Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05093387CT.gov SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | — | Withdrawn | — | — | — |
NCT05177796CT.gov Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | — | Withdrawn | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT03515798CT.gov Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03184558CT.gov Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | — | Terminated | — | — | — |
NCT02971748CT.gov Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT02411656CT.gov Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inflammatory Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Northwestern University | P2 | B · 60 |
| Trastuzumab | Hoffmann-La Roche | P3 | BBB |
| Cyclophosphamide | Northwestern University | P3 | BBB |
| Carboplatin | Northwestern University | P3 | BBB |
| Docetaxel | Association Tunisienne de lutte Contre le Cancer | P3 | BBB |
| Pertuzumab | Hoffmann-La Roche | P3 | BBB |
| Epirubicin | Northwestern University | P3 | BB |
| Adriamycin | M.D. Anderson Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | RenJi Hospital | P3 | BB |
+41 more in the Inflammatory Breast Carcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Inflammatory Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-inflammatory-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →